Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Obrocea Mihail

2. Date of Event Requiring Statement (Month/Day/Year)
07/27/2022

3. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [MAIA]

(Last)

(First)

(Middle)

444 WEST LAKE STREET, SUITE 1700

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Medical Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

CHICAGO, IL 60606

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	26,100 ⁽¹⁾	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options	⁽²⁾	01/05/2031	Common Stock	13,269	$ 1.8	D
Options	⁽²⁾	01/30/2031	Common Stock	6,131	$ 1.8	D
Options	⁽²⁾	04/04/2031	Common Stock	10,022	$ 1.83	D
Options	⁽³⁾	06/06/2031	Common Stock	7,447	$ 1.83	D
Options	⁽⁴⁾	06/04/2031	Common Stock	6,476	$ 1.83	D
Options	⁽⁵⁾	07/14/2031	Common Stock	260,000	$ 1.83	D
Option	⁽⁶⁾	06/29/2031	Common Stock	7,436	$ 1.83	D
Options	⁽⁷⁾	07/30/2031	Common Stock	772	$ 8	D
Warrants	⁽⁸⁾	⁽⁸⁾	Common Stock	8,820	$ 6	D
Warrants	⁽⁹⁾	⁽⁹⁾	Common Stock	4,230	$ 6	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Obrocea Mihail 444 WEST LAKE STREET, SUITE 1700 CHICAGO, IL 60606			Chief Medical Officer

Signatures

/s/ Mihail Obrocea		07/27/2022
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Mr. Obrocea beneficially owns 26,100 shares of common stock.
(2)	Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on May 11, 2021.
(3)	Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on June 7, 2021.
(4)	Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on June 5, 2021.
(5)	Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. 25% of these options vest in 1 year with the remaining options vesting in 36 equal monthly installments beginning on July 15, 2021.
(6)	Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on June 30, 2021.
(7)	Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on July 31, 2021.
(8)	Each Warrant became exercisable on the date of issuance of October 10, 2020, and expire on the earliest to occur of: (a) October 10, 2027 or (b) immediately prior to the closing of any change of control of the issuer.
(9)	Each Warrant became exercisable on the date of issuance of June 29, 2021, and expire on the earliest to occur of: (a) June 28, 2028 or (b) immediately prior to the closing of any change of control of the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.